PTC/SB/08s (08-03.)
Approved for use through 07/31/2006, OMB 0851-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Papernosh Reduction Act of 1995, no persons are required to respect to a contact on defense of ones of a contact on a contact

	INFORMATION DISCLOSURE	Filing Date		
		First Named Inventor Hiroy		a KONDOU
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		TBA	
	(Not for Submission and of a fix fixey	Examiner Name TBA		
		Attorney Docket Number		49288.2100

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion		of cited Document			s,Columns,Lines where ant Passages or Relevant s Appear	
	1										
If you wis	h to a	dd additional U.S. Publi		p		, , , , , , , , , , , , , , , , , , , ,		button			
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country	y Code ²	Kind Code ⁴		Name of Patente Applicant of cited Document	or v	vhere Rel	or Relevant	+=
	1	2002184151	JP			2002-06-28	TDK Corp.				Г
	2	2002288961	JP			2002-10-04	Fujitsu Ltd.				С
	3	2001126432	JP			2001-05-11	Hitachi Maxell Ltd.				С

If you wish to add additional Foreign Patent Document citation information please click the Add button

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)					
	Filing Date				
	First Named Inventor	Hiroy	a KONDOU		
	Art Unit		TBA		
	Examiner Name TBA				
	Attorney Docket Number		49288.2100		
NON-PATENT LITERATURE DOCUMENTS Remove					

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

T5

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

Application Number

publisher, city and/or country where published.

Evaminer Cite

Initials* No.

1				-					
If you wish to add add	If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE									
Examiner Signature Date Considered									
AFVANISTE INTERIOR OF THE PROPERTY OF THE PROP									

See Kind Codes of USPTO Patient Documents at view USPTO.000 or MPEP 901.04. Enter office that issued the document, by the hor-later code (WIPO Standard ST.3). For Japanese patient documents, the ndication of the year of the night of the Emperor must procede the serial number of the patient document.

*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here (
*Empirical hazaque shreation is stateded.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number		
	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Hiroya R		a KONDOU
(Not for submission under 37 CFR 1.99)	Art Unit		ТВА
(Not for Submission under 67 of it 1.55)	Examiner Name	TBA	
	Attorney Docket Number		49288.2100

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the ap	ppropriate sel	ection(s):	

hat each item of information contained in the information disclosure statement was first cited in any communication rom a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the formation disclosure statement.
normation disclosure statement.
r

OR

foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
statement.

See attached certification statement. Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18, Please see CFR 1.4(d) for the form of the signature

of the agranded							
Signature	/Shahpar Shahpar/	Date (YYYY-MM-DD)					
Name/Print	Shahnar Shahnar	Registration Number	45875				

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CPR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.